Compare ACADIA Pharmaceuticals Inc. (ACAD) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs MakeMyTrip Ltd — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while MakeMyTrip Ltd trades at $56.17 (market cap $5.57B). The key difference: MakeMyTrip Ltd is the larger of the two by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, MakeMyTrip Ltd nearer its low. Which is the better fit depends on your goals.
| ACAD | MMYT | |
|---|---|---|
Market Cap | $4.49B | $5.57B |
Sector | Health | Technology |
52-Week High | $28.06 | $103.21 |
52-Week Low | $20.06 | $36.30 |
Enterprise Value | $3.69B | $6.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
MakeMyTrip (MMYT) trades at $57.35, down 1.58% today but showing strong technical momentum with bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS beating expectations at $0.25 versus $0.1654, continuing a trend of earnings outperformance. Revenue reached $978.34M in 2025 with healthy 73.77% gross margins, though valuation metrics appear elevated with a P/E of 159.17. Analyst sentiment remains strongly positive with 72.73% buy ratings.
The outlook remains favorable given consistent earnings beats and strong travel demand recovery, though high valuation multiples and rising debt-to-asset ratios from 12.13% to 80.57% projected for 2026 present significant risks. Temporary travel disruptions have pressured growth, but platform resilience across hotel and package segments supports the bullish case. Investors should weigh growth potential against valuation concerns and increasing leverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
